Literature DB >> 17116782

Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature.

Douglas Leventhal1, Maxwell Furr, David Reiter.   

Abstract

Management of hypertrophic scars and keloids has advanced from crude, invasive methods such as gross excision and radiation to intralesional or topical agents that act on a cellular level. There is no universally accepted treatment regimen and no evidence-based literature to guide management. Our objectives are to present a list of available treatment regimens, their proposed mechanisms of action, and supporting evidence and to perform a meta-analysis of clinical trials to identify treatments with a better-than-even likelihood of improvement. We conducted a PubMed search through October 2005, identifying clinical studies of various treatments for hypertrophic scars and keloids. We graded the quality of each study, delineated the results into favorable vs nonfavorable, and calculated the statistical significance of the findings. The meta-analysis of 70 treatment series for various clinical measures showed a 70% chance of improvement with treatment; however, the mean amount of improvement to be expected was around 60%. There was no statistically significant difference between treatments. Most treatments for keloidal and hypertrophic scarring offer minimal likelihood of improvement. The magnitude of likely permanent improvement in any sign or symptom may be clinically meaningful but far short of cure. Novel therapies deserve further investigation but remain without proven benefit to date.

Entities:  

Mesh:

Year:  2006        PMID: 17116782     DOI: 10.1001/archfaci.8.6.362

Source DB:  PubMed          Journal:  Arch Facial Plast Surg        ISSN: 1521-2491


  57 in total

1.  Beyond the borders of keloid formation: A case report.

Authors:  S Cugno; D Rizis; C Cordoba
Journal:  Can J Plast Surg       Date:  2011

Review 2.  Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.

Authors:  Gerd G Gauglitz; Hans C Korting; Tatiana Pavicic; Thomas Ruzicka; Marc G Jeschke
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

Review 3.  Emerging Therapies for Scar Prevention.

Authors:  Lisa Block; Ankush Gosain; Timothy W King
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-10-01       Impact factor: 4.730

4.  Preventing Scars after Injury with Partial Irreversible Electroporation.

Authors:  Alexander Golberg; Martin Villiger; Saiqa Khan; Kyle P Quinn; William C Y Lo; Brett E Bouma; Martin C Mihm; William G Austen; Martin L Yarmush
Journal:  J Invest Dermatol       Date:  2016-07-05       Impact factor: 8.551

Review 5.  A primary care perspective on keloids.

Authors:  Steven Davidson; Nasir Aziz; Rashid M Rashid; Amor Khachemoune
Journal:  Medscape J Med       Date:  2009-01-20

Review 6.  Up-to-date approach to manage keloids and hypertrophic scars: a useful guide.

Authors:  Anna I Arno; Gerd G Gauglitz; Juan P Barret; Marc G Jeschke
Journal:  Burns       Date:  2014-04-24       Impact factor: 2.744

7.  Postoperative brachytherapy and electron beam irradiation for keloids: A single institution retrospective analysis.

Authors:  Qiwen Duan; Junhua Liu; Zhiguo Luo; Chenhao Hu
Journal:  Mol Clin Oncol       Date:  2015-01-27

Review 8.  Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.

Authors:  Saeid Amini-Nik; Yusef Yousuf; Marc G Jeschke
Journal:  Adv Drug Deliv Rev       Date:  2017-07-27       Impact factor: 15.470

9.  Scar formation following excisional and burn injuries in a red Duroc pig model.

Authors:  Britani N Blackstone; Jayne Y Kim; Kevin L McFarland; Chandan K Sen; Dorothy M Supp; J Kevin Bailey; Heather M Powell
Journal:  Wound Repair Regen       Date:  2017-07-31       Impact factor: 3.617

Review 10.  Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions.

Authors:  Clement D Marshall; Michael S Hu; Tripp Leavitt; Leandra A Barnes; H Peter Lorenz; Michael T Longaker
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-02-01       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.